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Intravenous (iv) infusion of high-dose ascorbic acid (AA) has been used as a treatment for cancer pa-
tients. The tumoricidal action of AA occurs due to its prooxidant effect. Erythorbic acid (EA), one of the
AA epimers, has reduced vitamin C activity, while the antioxidant activity of EA is similar to that of AA.
Currently, other physiological and pharmacological functions of EA are not well known. We examined the
cytotoxicity of EA to murine colon carcinoma (colon-26) cells and the antitumor activity of EA in tumor-
bearing mice. Cytotoxic activity of EA to colon-26 cells was evaluated by using the calcein-AM assay. EA
showed the same cytotoxic activity to colon-26 cells as that of AA. The cytotoxicity of EA was shown to be
caused by oxidative stress. Next, colon-26 tumor-bearing mice were iv administered EA and AA on al-
ternate days for 4 times, and tumor growth rates were measured. Tumor growth was signiﬁcantly in-
hibited by administration of high-dose EA in vivo as well as AA. Finally, the in vivo biodistribution and
clearance of EA and AA were investigated in tumor-bearing mice. Endogenous AA in the tumor was
consumed to resist oxidative stress caused by reactive oxygen species that was generated by adminis-
tered EA. These results indicated that the oxidative stress-mediated antitumor activity is one of the
pharmacological functions of high-dose iv EA.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ascorbic acid (AA, Fig. 1A) is a water-soluble compound known
as vitamin C, and it is common knowledge that AA is an essential
micronutrient for humans. AA shows various physiological and
pharmacological activities, including collagen synthesis [1], drug
metabolism [2], enhancing iron absorption [3] and antioxidant
activity [4]. A number of recent publications report the prooxidant
effects of antioxidants (e.g., resveratrol, quercetin, and curcumin)
at high concentrations [5–7]. In the presence of transition metal
ions such as iron and copper, high-concentration AA can exert
prooxidant effects on a tumor, and it has been used by some
practitioners as an intravenous (iv) infusion to treat cancer [8,9].
Intravenous infusion of high-dose AA temporarily increases the
plasma concentration of AA in patients to a level 100–1000-times
than that of healthy levels (from 50–100 μM to 25–30 mM) [10,11],
while the upper limit value of oral administration was predicted to
be approximately 220 μM [12]. Pharmacologic AA acts as a pro-
oxidant agent. AA reduces ferric iron (Fe3þ) to ferrous iron (Fe2þ),
and Fe2þ acts as an electron donor to O2, ultimately generating
H2O2 in plasma and extracellular ﬂuid. H2O2 then interacts withB.V. This is an open access article uanother transition metal to generate ROS, including the highly
reactive hydroxyl radical [11,13–15]. In normal cells that have
antioxidant enzymes such as catalase and glutathione peroxidase,
ROS are immediately detoxiﬁed [14]. On the other hand, many
cancer cells have low levels of several antioxidant enzymes [16].
The mitochondria in many cancer cells may have increased sen-
sitivity to ROS. Therefore, mitochondria of cancer cells that have
low anti-oxidant capacity are damaged by ROS [14], resulting in
cell death due to a decrease in ATP production [14,17,18]. High-
dose iv AA therapy exhibits a cytotoxic activity selectively to
cancer cells and has fewer adverse effects than other cancer
treatments.
Erythorbic acid (EA, Fig. 1A), a stereoisomer of AA, only differs
from AA in the relative position of the hydrogen and hydroxyl
groups on the ﬁfth carbon atom. EA shows chemical properties
similar to those of AA; however, the antiscorbutic activity of EA
has been reported to be about one-twentieth of that of AA in vivo
[19] and EA has only one-eighth of the activity of AA for stimu-
lating collagen synthesis in vitro [20] because of the difference in
quantity of intracellular uptake. It is believed that EA has a neg-
ligible vitamin C activity. On the other hand, EA has the same level
of activity as that of AA for stimulating proline hydroxylation re-
action [20]. Also, EA administration enhances iron absorption from
Fe2þ sulfate more than does AA [21]. The antioxidant activity of EA
is similar to that of AA, and EA has been widely used as annder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Structures and oxidative stress-induced cytotoxicity of AA and EA. (A) Structures of AA and EA. (B) In vitro cytotoxicity of EA and AA. Colon-26 cells were incubated in
a medium containing EA or AA at indicated concentrations for 24 h. Vehicle-treated cells were arbitrarily set as 100% control viability. (C)–(E) Amount of ROS generated by EA
or AA in colon-26 cells. They were then treated with EA or AA (2 mM) for indicated times (C, 15 min; D, 30 min; E, 60 min). Results are expressed as percentage (%) relative to
each control value. All data represent means 7 SD of three independent cultures (*Po0.05; **Po0.01, compared to control).
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known about EA beyond these physiological functions.
Since EA has antioxidant activity similar to that of AA, it can be
expected that high-dose iv EA will also act as a prooxidant like AA.
However, there have been few studies in which the anticancer
activity of high-dose iv EA was investigated. Administration of a
relatively low dose of AA or EA intraperitoneally to a human
mammary tumor xenograft mouse was reported not to inhibit
tumor growth. However, when cupric sulfate was added to the
injection ﬂuid, tumor growth was depressed [22]. The aim of the
present study was to ﬁnd a new pharmacological function of EA.
For this purpose, we assessed the antitumor activity of high-dose
iv EA to murine colon carcinoma cells (colon-26) and cancer model
mice. We also investigated the in vivo biodistribution and clear-
ance of EA in tumor-bearing mice.2. Materials and methods
2.1. Chemicals
Sodium erythorbate monohydrate (EA-Na H2O) was obtained
from Tokyo Chemical Industries (Tokyo, Japan). Sodium ascorbate
(AA-Na), heparin, calcein-AM solution and 2′,7′-dichlorodihydro-
ﬂuorescein diacetate (DCFH-DA) were purchased from Wako Pure
Chemical Industries (Osaka, Japan). RPMI 1640 medium was pur-
chased from Corning (NY, USA). Fetal bovine serum (FBS, heat-
inactivated) was from HyClone (Logan, UT, USA). Triton X-100 was
from Sigma (St. Louis, MO, USA). Dithiothreitol (DTT) was obtained
from Nacalai tesque (Kyoto, Japan).2.2. Cell lines
Murine colon carcinoma (colon-26) cells were purchased from
RIKEN BRC CELL BANK (Tsukuba, Japan). Colon-26 cells were
grown in RPMI 1640 with 10% FBS, 100 units/mL penicillin and
100 μg/mL streptomycin at 37 °C in 5% CO2. Experiments were
performed when cell growth was approximately 80% conﬂuent.
2.3. Evaluation of in vitro cytotoxicity of EA
Cytotoxicity of EA to colon-26 cells was assessed using calcein-
AM. The cells were suspended in RPMI 1640 medium and seeded
in a 96-well microplate at a density of 1.0104 cells/100 μL/well
and then incubated for 24 h at 37 °C in 5% CO2. After incubation,
each medium was replaced with 90 μL of fresh medium and then
10 μL each of AA-Na and EA-Na were added and the cells in-
cubated for 24 h. The cells were then washed with 100 μL of PBS(-)
and added 100 μL of calcein-AM solution (5 μM). After 30 min of
incubation, 20 μL of 0.6% Triton X-100 solution was added to each
well. The ﬂuorescence intensity (FI) of the cell lysate was recorded
on a microplate reader (Varioskan Flash from Thermo Scientiﬁc,
Ex. 485 nm, Em. 527 nm). Cell viability (%) was caluculated as (FI of
treated-FI of blank )/(FI of control-FI of blank)100. The differ-
ence in cell viability between the control and treatment was
analyzed by Dunnett’s test (**Po0.01).
2.4. DCFH-DA assay
The relative amount of reactive oxygen species (ROS) to the
control value was assessed by using DCFH-DA. Colon-26 cells were
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croplate at a density of 1.0104 cells/90 μL/well and then in-
cubated for 24 h at 37 °C in 5% CO2. After incubation, 10 μL of
DCFH-DA (5 μM) was added to each well and the cells were in-
cubated for 20 min. The cells were then washed with 100 μL of
fresh medium. The medium was replaced by 100 μL of AA-Na or
EA-Na solution (2 mM) and the cells were incubated for the in-
dicated periods. The cells were sonicated for several seconds with
100 μL of 0.1% Triton X-100. Fluorescence intensity of the cell ly-
sate was measured by Varioskan Flash (Ex. 485 nm, Em. 527 nm).
The difference in ﬂuorescence intensity between the control and
treatment was analyzed by Dunnett’s test (*Po0.05, **Po0.01).
2.5. Evaluation of in vivo antitumor activity of EA
The antiproliferative activity of EA was investigated in colon-26
xenograft mice. Colon-26 cells were implanted at a density of
1.0106 cells in ﬁve-week-old female Balb/c mice (CLEA Japan,
Tokyo, Japan) subcutaneously in the left and right dorsal areas.
When transplanted tumor sizes were more than 10 mm in dia-
meter, the tumors were excised and small pieces of the tumor
(approximately 2-mm cubes) were engrafted subcutaneously into
the left dorsal area of each ﬁve-week-old male CDF1 mice (Japan
SLC, Shizuoka, Japan). When tumor sizes had reached 8–10 mm in
diameter after implantation, the mice were used for studies of
antitumor activity, biodistribution and clearance of EA-Na and AA-
Na. EA and AA samples were dissolved in PBS (equimolecular
amount of 300 mg/kg body weight of AA) was injected in-
travenously into colon-26 tumor-bearing mice on alternate days
for 4 times. Tumor size was calculated from caliper measurements
using volume¼(length) (width)20.5. The differences in tumor
size between the treatment groups and control group were ana-
lyzed by Dunnett’s test (*Po0.05, **Po0.01). The experiments
were approved by the Committee for Ethics in Animal Experi-
ments of the Prefectural University of Hiroshima.
2.6. In vivo biodistribution and clearance of EA
EA and AA were injected intravenously into tumor-bearing
CDF1 mice. The mice were sacriﬁced under anesthesia by iso-
ﬂurane. The liver, kidney, tumor and blood were collected at 15,
30, 60, 180 and 360 min (n¼4) after injection. A blood sample was
collected by heart puncture into a heparin-coated syringe. Plasma
was separated from whole blood by centrifugation at 10,000g for
10 min at 4 °C. The samples were stored at 80 °C until analysis.
Samples were homogenized with 85% acetonitrile including
250 mg/L of DTT (100 mg wet tissue or 100 μL plasma/400 μL
solution). Then all samples were centrifuged at 10,000g for 10 min
at 4 °C and the supernatants were collected. The supernatants
were analyzed by HPLC. Separation for EA and AA was achieved by
isocratic elution of an HILIC column (ϕ4.6250 mm, 5 μm, GL
Sciences Inc., Tokyo) kept at 40 °C with 85% acetonitrile/66.7 mM
ammonium acetate at a ﬂow rate of 0.7 mL/min [23]. The absor-
bance at 260 nm was monitored. The mean con-
centration7standard error of the mean (SE) was calculated for
each time point.Fig. 2. Tumor growth in colon-26 tumor-bearing CDF1 mice treated with EA or AA.
Tumor sizes were measured for 7 days during treatment. All data represent
means7SE (n¼6). (*Po0.05, **Po0.01, compared with the control).3. Results and discussion
3.1. In vitro cytotoxic activity of EA
The tumoricidal action of high-dose AA occurs due to genera-
tion of extracellular ROS such as H2O2 by reduction of catalytic
metals [13]. Since the two isomers EA and AA are equally effective
at reducing, it was expected that high-dose EA also exhibitscytotoxicity similar to that of AA. First, EA was tested for its effect
on colon-26 cells using the calcein-AM assay (Fig. 1B). EA exhibited
cytotoxic activity to colon-26 cells in a concentration-dependent
manner, and there was a signiﬁcant toxic effect at a concentration
of more than 0.6 mM. The toxicity proﬁles of EA and AA were si-
milar (EC50 of 0.67 and 0.75 mM, respectively). As expected, EA as
well as AA exhibited cytotoxic activity to colon-26 cells at the high
concentrations. It is thought that the cytotoxicity of EA is due to
generation of ROS.
We then evaluated the relative quantity of intracellular ROS to
the control by using a ﬂuorescent ROS-sensitive probe, DCFH-DA.
Fig. 1C–E shows the change in intracellular ROS. At 15 min after
exposure of cells to EA at the concentration of 2 mM, a slight in-
crease in intracellular ROS was detected (Fig. 1C). At 30 min, the
amount of ROS was signiﬁcantly increased by EA treatment and
reached approximately 3 times that of the control (Fig. 1D). There
was little increase in ROS at 60 min, but the level was higher than
that of the control (Fig. 1E). EA and AA generated similar levels of
ROS at similar concentrations. The maximum generation of ROS
was detected at 30 min. This result agrees with results reported by
Verrax et al. showing that ROS was generated by exposure to a
pharmacologic concentration of AA for 30 min [24]. These results
indicate that EA has oxidative stress-mediated antitumor activity
similar to that of AA in vitro.
3.2. In vivo antitumor activity of EA
To evaluate the inhibitory effects on tumor growth, we used a
xenograft colon cancer model in CDF1 mice. The model mice were
treated (iv injection) with a placebo (phosphate buffered saline:
PBS), EA-Na or AA-Na (equimolecular amount of 300 mg/kg of AA)
on alternate days for 4 times. As shown in Fig. 2, the difference
between tumor growth in the placebo group and that in the EA-
treated group was statistically signiﬁcant at day 6. In the AA-
treated group, the inhibition ratio of tumor growth was the same
as that in the EA-treated group. A signiﬁcant difference was ob-
served in the tumor growth between the placebo group and the
AA-treated group at day 5. It is expected that high-dose iv EA has
the same antitumor activity as that of AA. The antitumor activity of
AA only tended to decrease tumor growth but not completely
inhibit, and this was always the case for AA as a single agent in
some earlier works [11,15]. In a clinical setting, depending on the
condition of the patient, AA is administered at a dose of several
dozen grams or more [25]. The plasma AA level must be raised up
to 20 mM or more to obtain a sufﬁcient therapeutic effect. Infusion
of 0.9–1.5 g/kg AA resulted in elevation of AA level to 17–26 mM in
AB
Liver
Fig. 3. In vivo biodistribution of AA in colon-26 tumor-bearing CDF1 mice. AA was
injected intravenously into colon-26 tumor-bearing CDF1 mice. Liver, kidney, tu-
mor (A) and plasma (B) samples from tumor-bearing mice were analyzed at the
indicated times after injection. All data represent means7SE (n¼4). *Po0.05,
signiﬁcant difference of tumor AA levels at each time point compared with at 0 min
(Dunnett’s test).
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kg body weight) compared with that in clinical cases, and AA
therefore showed weak activity [26]. Our results showed that tu-
mor growth was signiﬁcantly decreased by an intravenous shot of
EA and AA, and stronger antitumor activity might have been
shown if the mice had been given EA and AA by drip infusion.
3.3. In vivo biodistribution and clearance of EA
Little is known about the pharmacokinetics of AA after iv ad-
ministration of AA under a cancer condition. Padayatty et al. ex-
amined AA pharmacokinetics only in blood of healthy people [12].
Kim et al. carried out an in vivo study of a radiotracer, 6-deoxy-6-
iodo-L-ascorbic acid, in tumor-bearing mice, though they did not
provide data for endogenous AA levels in the tumor [27]. There-
fore, we studied the biodistribution and clearance of AA in tumor-
bearing mice. Fig. 3 shows the distribution of AA in mouse liver,
kidney, tumor (Fig. 3A) and plasma (Fig. 3B) for periods ranging
from 15 to 360 min after iv injection of AA-Na (equimolecular of
300 mg/kg of AA). The AA levels in the liver (initial value:
1.1 μmol/mg), kidney (0.6 μmol/mg) and plasma (57.1 μM) sub-
stantially increased in the ﬁrst 15 min. The maximum values of AA
in the liver, kidney and plasma were 2.2, 2.7 μmol/mg and 1.6 mM,
respectively. The increased levels in the ﬁrst 15 min decreased to
baseline levels after 1 h. In contrast, the AA levels in the tumor
were decreased by administration of high-dose AA (Fig. 3A).
Generally, a tumor takes up AA positively, and AA concentration in
a tumor is maintained at a high level [28]. Therefore, it was ex-
pected that iv injection of high-dose AAwould increase the level ofAA in the tumor. Surprisingly, the amount of AA in the tumor was
not increased but rather reduced at 15 min after administration of
AA. Fifteen minutes after administration of 300 mg/kg iv AA, tu-
mor levels had signiﬁcantly decreased to 1.4 μmol/mg, while
plasma levels were 1.6 mM, a concentration shown to be cytotoxic
in vitro (Fig. 3B). Since exposure of colon-26 cells to AA increased
intracellular ROS (Fig. 1C–E), it was thought that the cells were
exposed to oxidative stress. Thus, at 15 min in the in vivo experi-
ment, the tumor might have been exposed to oxidative stress
(Fig. 3A). The results suggest that ROS were generated in the ex-
tracellular ﬂuid by high dose iv AA. The resulting oxidative stress
in the tumor cells was alleviated by oxidizing endogenous AA.
After an initial recovery of endogenous AA levels, these decreased
again (Fig. 3A), suggesting that ROS-induced damage either af-
fected AA uptake from plasma or had resulted in a free radical
cascade which continued to deplete endogenous AA levels. As
shown in Fig. 1D, the greatest increase in intracellular ROS was
detected at 30 min after exposure to AA in vitro. The time when
the tumor received an oxdative stress in vivo was earlier than the
time when the tumor cells showed the highest ROS concentration
in vitro. It seems that ROS was generated in vivo more rapidly than
in vitro because many transition metals exist in the body. These
results suggest that the tumor may be injured by oxidative stress
of ROS generated by AA.
Subsequently, the pharmacokinetic of EA was investigated. The
EA levels in tissues in the EA-treated group were measured
(Fig. 4A and B). Amounts of EA in the liver, kidney and plasma had
peaked at 15 min after administration of EA and then decreased. At
15 min, the uptake quantities of EA after injection of EA in the liver
and plasma were 1.4 μmol/mg and 1.5 mM, respectively, and these
amounts were the same as levels of AA of which were increased by
AA administration. In contrast, the amount of EA in the kidney
(4.4 μmol/mg, Fig. 4A) was larger than that of AA in AA-treated
group (2.7 μmol/mg, Fig. 3A). This result suggests that EA is ex-
creted faster than AA. Uptake of EA into the tumor was also ob-
served. The amount of EA in the tumor was kept at a ﬁxed value,
though the amounts of EA in other tissues decreased with time.
Interestingly, administration of EA affected the amounts of AA in
the plasma and tumor (Fig. 4C and D). AA in the kidney and liver
was not inﬂuenced (Fig. 4C), but plasma AA level was increased to
105.8 μM from the initial value of 56.0 μM at 15 min after EA in-
jection (Fig. 4D). The increase level of AA in plasma had decreased
to the initial level at 1 h. It cannot be assumed that the increment
of AA by EA injection was due to efﬂux of AA from tissues by EA
because AA levels in the liver and the kidney showed little change.
The oxidized form of AA, dehydroascorbic acid (DHA), might be
deoxidized to AA by reduction activity of EA. However, under
phygiological conditions, since DHA concentrations in plasma re-
main extremely low [29,30], it is difﬁcult to think that the amount
of AA was increased twice by reduction from DHA in plasma. It
was reported that the AA level in plasma of cancer patients
(29727 μM) was reduced compared to that in a normal condition
(50729 μΜ) [31]. Thus, the DHA plasma level under a cancer
condition might be higher than that under a normal condition.
These results suggested that EA reduces DHA in plasma to AA. As
shown in Fig. 4C, the AA level in the tumor decreased immediately
after the injection of EA, and the level of AA had returned to the
initial level at 60 min. After that, the content of AA in the tumor
decreased slowly until 6 h, while the content of EA in the tumor
increased slightly. The time-course proﬁle of AA concentration in
the tumor agrees well with that seen by AA injection (Fig. 3A:
tumor). These results suggested that the decrease of AA in the
tumor with EA injection was due to oxidative stress, not efﬂux of
AA by competitive uptake of EA. On the other hand, the amounts
of AA in the liver and kidney showed little change. Hence, it is
thought that only the tumor was exposed to oxidative stress by
A B
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Fig. 4. In vivo biodistribution of EA and inﬂuence of EA on quantity of AA in colon-26 tumor-bearing CDF1 mice. EA was injected intravenously into colon-26 tumor-bearing
CDF1 mice. Amounts of EA (A) and (B) and AA (C) and (D) in the liver, kidney, tumor and plasma after administration of EA. All samples from tumor-bearing mice were
analyzed at the indicated times after injection. All data represent means7SE (n¼4).
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shows cytotoxic activity selectively to tumor and has few adverse
effects on normal tissues.4. Conclusions
The results of the present study showed that high-dose EA has
antitumor activity in vitro and in vivo. Exposure of cells to EA
increased intracellular ROS, and iv administration of EA to tumor-
bearing mice temporarily decreased AA level in the tumor. These
results indicate that the antitumor activity of EA was caused by
damage to the tumor from ROS generated by its own oxidation.
We propose oxidative stress-mediated antitumor activity as one of
the unknown pharmacological functions of high-dose iv EA to
colon-26 cells and cancer model mice.Acknowledgment
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